Cite
MLA Citation
Meletios A Dimopoulos et al.. “Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial.” Lancet oncology, vol. 18, no. 2, n.d., pp. 241–250. http://access.bl.uk/ark:/81055/vdc_100041272522.0x000032